Your session is about to expire
← Back to Search
Study Summary
This trial will test if satralizumab is safe and effective in treating generalized myasthenia gravis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 85 Patients • NCT02028884Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with generalized Myasthenia Gravis.You have a score of 5 or more on the MG-ADL test, with most points coming from non-eye-related symptoms.You have tested positive for hepatitis B virus (HBV) or hepatitis C virus (HCV).I am currently on a stable dose of medication for myasthenia gravis.Your myasthenia gravis is classified as moderate to severe.I have had severe eye-related symptoms or a myasthenic crisis in the last 3 months.I had my thymus gland removed within the last year.I have not received a live vaccine in the last 6 weeks.My parents or guardian and I have both agreed to my participation in the study.I do not have any health conditions that could affect the study.You have signs of tuberculosis, unless you are already taking medicine to prevent it.
- Group 1: Satralizumab
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any known serious side effects to taking Satralizumab?
"There is some evidence that suggests satralizumab is effective and multiple rounds of data that support its safety, thus it received a 3 on our safety scale."
What have been the previous findings of other research groups when studying Satralizumab?
"There are currently 2 active clinical trials researching satralizumab. Of those, 2 are in Phase 3. Mendoza and Guipuzcoa have the most active trials for this medication, but there are a total of 181 clinical trial sites."
Is this trial taking place at a lot of hospitals in North America?
"Currently, the study is live at 18 clinical sites. Some of these locations include Pasadena, Jacksonville and Chicago. To minimize the burden of travelling, it is encouraged that patients select the trial site closest to their location."
Have patients undergone this experimental treatment before?
"There are 2 ongoing studies concerning the effects of satralizumab in 56 different cities and 26 countries. The first study, which was completed in 2021, was sponsored by Hoffmann-La Roche. It involved 127 patients and finished its Phase 3 drug approval stage. Since 2021, there have been 18240 similar studies conducted."
Share this study with friends
Copy Link
Messenger